{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:09:04Z","timestamp":1784290144343,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Microsatellite-stable\/proficient mismatch repair (MSS\/pMMR) colorectal cancer (CRC) is characterized by a cold tumor microenvironment, with limited CD8\u207a T cell infiltration and poor responsiveness to immune checkpoint inhibitors (ICIs). Here, using an in vivo CRISPR\/Cas9 screen in a CMT93 cell-derived murine tumor model, we identify\n                    <jats:italic>Arid3b<\/jats:italic>\n                    as a key negative regulator of CD8\u207a T cell infiltration and antitumor activity. Genetic ablation of\n                    <jats:italic>Arid3b<\/jats:italic>\n                    in CD8\u207a T cells significantly enhances their intratumoral accumulation and promotes robust tumor control. Mechanistically,\n                    <jats:italic>Arid3b<\/jats:italic>\n                    deficiency upregulates\n                    <jats:italic>Runx3<\/jats:italic>\n                    , driving a tissue-resident memory-like phenotype and effector function. Notably, the benefits conferred by\n                    <jats:italic>Arid3b<\/jats:italic>\n                    deficiency are abrogated upon\n                    <jats:italic>Runx3<\/jats:italic>\n                    deletion, indicating a RUNX3-dependent mechanism. Together, targeting ARID3B could offer a promising strategy to reshape the tumor microenvironment and sensitize MSS CRC to immunotherapy.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-73241-7","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:54:49Z","timestamp":1778853289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Arid3b suppresses CD8\u2009+\u2009T cell infiltration and function in microsatellite-stable colorectal cancer via Runx3"],"prefix":"10.1038","volume":"17","author":[{"given":"Shuo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-6753","authenticated-orcid":false,"given":"Ce","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haorui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6538-897X","authenticated-orcid":false,"given":"Yiteng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6475-0463","authenticated-orcid":false,"given":"Deng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjiang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3905-3244","authenticated-orcid":false,"given":"Zexian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8415-7587","authenticated-orcid":false,"given":"Zhidong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"73241_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"73241_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.trecan.2024.01.008","volume":"10","author":"NP Tjader","year":"2024","unstructured":"Tjader, N. P. & Toland, A. E. Immunotherapy for colorectal cancer: insight from inherited genetics. Trends Cancer 10, 444\u2013456 (2024).","journal-title":"Trends Cancer"},{"key":"73241_CR3","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.trecan.2024.05.001","volume":"10","author":"M Singh","year":"2024","unstructured":"Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S. & Kopetz, S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer 10, 598\u2013609 (2024).","journal-title":"Trends Cancer"},{"key":"73241_CR4","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-21-0557","volume":"27","author":"SJ Casak","year":"2021","unstructured":"Casak, S. J. et al. FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H\/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin. Cancer Res. 27, 4680\u20134684 (2021).","journal-title":"Clin. Cancer Res."},{"key":"73241_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1440830","volume":"15","author":"Q Wang","year":"2024","unstructured":"Wang, Q., Yu, M. & Zhang, S. The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies. Front. Immunol. 15, 1440830 (2024).","journal-title":"Front. Immunol."},{"key":"73241_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0620-6","volume":"16","author":"M Angelova","year":"2015","unstructured":"Angelova, M. et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 16, 64 (2015).","journal-title":"Genome Biol."},{"key":"73241_CR7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182\u20131191 (2017).","journal-title":"Lancet Oncol."},{"key":"73241_CR8","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"73241_CR9","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med."},{"key":"73241_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh, K. et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 16, 361\u2013375 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"73241_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1570-z","volume":"16","author":"SS Liu","year":"2018","unstructured":"Liu, S. S. et al. Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients. J. Transl. Med. 16, 195 (2018).","journal-title":"J. Transl. Med."},{"key":"73241_CR12","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960\u20131964 (2006).","journal-title":"Science"},{"key":"73241_CR13","first-page":"1086","volume":"24","author":"Q Zou","year":"2021","unstructured":"Zou, Q., Hu, B., Yu, H. C. & Ren, D. L. Characteristics of CD8+ T cell infiltration in colorectal cancer and their correlation with prognosis. Zhonghua Wei Chang Wai Ke Za Zhi 24, 1086\u20131092 (2021).","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"73241_CR14","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1038\/onc.2012.285","volume":"32","author":"K Kobayashi","year":"2013","unstructured":"Kobayashi, K., Jakt, L. M. & Nishikawa, S. I. Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn. Oncogene 32, 2640\u20132648 (2013).","journal-title":"Oncogene"},{"key":"73241_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.celrep.2015.12.064","volume":"14","author":"TT Liao","year":"2016","unstructured":"Liao, T. T. et al. let-7 modulates chromatin configuration and target gene repression through regulation of the ARID3B complex. Cell Rep. 14, 520\u2013533 (2016).","journal-title":"Cell Rep."},{"key":"73241_CR16","doi-asserted-by":"publisher","unstructured":"Saadat, K. et al. Distinct and overlapping roles of ARID3A and ARID3B in regulating E2F\u2011dependent transcription via direct binding to E2F target genes. Int. J. Oncol. https:\/\/doi.org\/10.3892\/ijo.2021.5192 (2021).","DOI":"10.3892\/ijo.2021.5192"},{"key":"73241_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ydbio.2005.12.016","volume":"293","author":"A Takebe","year":"2006","unstructured":"Takebe, A. et al. Microarray analysis of PDGFR alpha+ populations in ES cell differentiation culture identifies genes involved in differentiation of mesoderm and mesenchyme including ARID3b that is essential for development of embryonic mesenchymal cells. Dev. Biol. 293, 25\u201337 (2006).","journal-title":"Dev. Biol."},{"key":"73241_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13402-014-0185-5","volume":"37","author":"AS Oguz Erdogan","year":"2014","unstructured":"Oguz Erdogan, A. S., Ozdemirler, N., Oyken, M., Alper, M. & Erson-Bensan, A. E. ARID3B expression in primary breast cancers and breast cancer-derived cell lines. Cell Oncol. 37, 289\u2013296 (2014).","journal-title":"Cell Oncol."},{"key":"73241_CR19","doi-asserted-by":"publisher","first-page":"8331","DOI":"10.1158\/0008-5472.CAN-06-0756","volume":"66","author":"K Kobayashi","year":"2006","unstructured":"Kobayashi, K., Era, T., Takebe, A., Jakt, L. M. & Nishikawa, S. ARID3B induces malignant transformation of mouse embryonic fibroblasts and is strongly associated with malignant neuroblastoma. Cancer Res. 66, 8331\u20138336 (2006).","journal-title":"Cancer Res"},{"key":"73241_CR20","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.7150\/thno.44147","volume":"10","author":"TT Liao","year":"2020","unstructured":"Liao, T. T. et al. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer. Theranostics 10, 6095\u20136112 (2020).","journal-title":"Theranostics"},{"key":"73241_CR21","doi-asserted-by":"publisher","first-page":"e0131961","DOI":"10.1371\/journal.pone.0131961","volume":"10","author":"A Bobbs","year":"2015","unstructured":"Bobbs, A. et al. ARID3B directly regulates ovarian cancer promoting genes. PLoS ONE 10, e0131961 (2015).","journal-title":"PLoS ONE"},{"key":"73241_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/10732748231169403","volume":"30","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Over-expression of ARID3B suppresses tumor progression and predicts better prognosis in patients with gastric cancer. Cancer Control 30, 10732748231169403 (2023).","journal-title":"Cancer Control"},{"key":"73241_CR23","doi-asserted-by":"publisher","unstructured":"Kearney, C. J. et al. Tumor immune evasion arises through loss of TNF sensitivity. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aar3451 (2018).","DOI":"10.1126\/sciimmunol.aar3451"},{"key":"73241_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.trecan.2018.03.002","volume":"4","author":"RD Chow","year":"2018","unstructured":"Chow, R. D. & Chen, S. Cancer CRISPR screens in vivo. Trends Cancer 4, 349\u2013358 (2018).","journal-title":"Trends Cancer"},{"key":"73241_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413\u2013418 (2017).","journal-title":"Nature"},{"key":"73241_CR26","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770\u2013775 (2018).","journal-title":"Science"},{"key":"73241_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"73241_CR28","doi-asserted-by":"publisher","first-page":"D174","DOI":"10.1093\/nar\/gkad1059","volume":"52","author":"I Rauluseviciute","year":"2024","unstructured":"Rauluseviciute, I. et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 52, D174\u2013d182 (2024).","journal-title":"Nucleic Acids Res."},{"key":"73241_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/ni.2518","volume":"14","author":"BS Reis","year":"2013","unstructured":"Reis, B. S., Rogoz, A., Costa-Pinto, F. A., Taniuchi, I. & Mucida, D. Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4\u207a T cell immunity. Nat. Immunol. 14, 271\u2013280 (2013).","journal-title":"Nat. Immunol."},{"key":"73241_CR30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/ni.3773","volume":"18","author":"Q Shan","year":"2017","unstructured":"Shan, Q. et al. The transcription factor Runx3 guards cytotoxic CD8(+) effector T cells against deviation towards follicular helper T cell lineage. Nat. Immunol. 18, 931\u2013939 (2017).","journal-title":"Nat. Immunol."},{"key":"73241_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature24993","volume":"552","author":"JJ Milner","year":"2017","unstructured":"Milner, J. J. et al. Runx3 programs CD8(+) T cell residency in non-lymphoid tissues and tumours. Nature 552, 253\u2013257 (2017).","journal-title":"Nature"},{"key":"73241_CR32","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","volume":"181","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell 181, 442\u2013459.e429 (2020).","journal-title":"Cell"},{"key":"73241_CR33","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","volume":"576","author":"J Wei","year":"2019","unstructured":"Wei, J. et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature 576, 471\u2013476 (2019).","journal-title":"Nature"},{"key":"73241_CR34","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2021.02.019","volume":"184","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. In vivo CD8(+) T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell 184, 1262\u20131280.e1222 (2021).","journal-title":"Cell"},{"key":"73241_CR35","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1242\/dev.109918","volume":"141","author":"V Uribe","year":"2014","unstructured":"Uribe, V. et al. Arid3b is essential for second heart field cell deployment and heart patterning. Development 141, 4168\u20134181 (2014).","journal-title":"Development"},{"key":"73241_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154948","volume":"252","author":"S Nasuh","year":"2023","unstructured":"Nasuh, S. et al. ARID3A and ARID3B exert direct regulatory control over the long non-coding RNAs (lncRNAs) MALAT1 and NORAD within the context of non-small cell lung cancer (NSCLC). Pathol. Res. Pr. 252, 154948 (2023).","journal-title":"Pathol. Res. Pr."},{"key":"73241_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1058726","volume":"12","author":"T Liu","year":"2022","unstructured":"Liu, T. et al. MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma. Front. Oncol. 12, 1058726 (2022).","journal-title":"Front. Oncol."},{"key":"73241_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01768-0","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Epigenetic reprogramming of Runx3 reinforces CD8\u2009+\u2009T-cell function and improves the clinical response to immunotherapy. Mol. Cancer 22, 84 (2023).","journal-title":"Mol. Cancer"},{"key":"73241_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110337","volume":"95","author":"H Cheng","year":"2022","unstructured":"Cheng, H. et al. G protein-coupled receptor kinase type 2 and \u03b2-arrestin2: key players in immune cell functions and inflammation. Cell Signal 95, 110337 (2022).","journal-title":"Cell Signal"},{"key":"73241_CR40","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.immuni.2025.02.007","volume":"58","author":"C Luo","year":"2025","unstructured":"Luo, C. et al. Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. Immunity 58, 745\u2013765.e749 (2025).","journal-title":"Immunity"},{"key":"73241_CR41","doi-asserted-by":"publisher","unstructured":"Tang, K. et al. Perturbation of calreticulin potentiates CD8+ T cell-mediated antitumor immunity. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20242360 (2025).","DOI":"10.1084\/jem.20242360"},{"key":"73241_CR42","doi-asserted-by":"publisher","unstructured":"Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abh2169 (2021).","DOI":"10.1126\/sciadv.abh2169"},{"key":"73241_CR43","doi-asserted-by":"publisher","unstructured":"Uhlen, M. et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. Science https:\/\/doi.org\/10.1126\/science.aax9198 (2019).","DOI":"10.1126\/science.aax9198"},{"key":"73241_CR44","unstructured":"The UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2025. Nucleic Acids Res. 53, D609\u2013D617 (2025)."},{"key":"73241_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2018.15","volume":"5","author":"S Bhattacharya","year":"2018","unstructured":"Bhattacharya, S. et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci. Data 5, 180015 (2018).","journal-title":"Sci. Data"},{"key":"73241_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C. & Vazquez, F. The present and future of the cancer dependency map. Nat. Rev. Cancer 25, 59\u201373 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"73241_CR47","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"73241_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07901-8","volume":"9","author":"KR Sanson","year":"2018","unstructured":"Sanson, K. R. et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat. Commun. 9, 5416 (2018).","journal-title":"Nat. Commun."},{"key":"73241_CR49","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0301-472X(03)00260-1","volume":"31","author":"T Kitamura","year":"2003","unstructured":"Kitamura, T. et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp. Hematol. 31, 1007\u20131014 (2003).","journal-title":"Exp. Hematol."},{"key":"73241_CR50","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gky354","volume":"46","author":"JP Concordet","year":"2018","unstructured":"Concordet, J. P. & Haeussler, M. CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens. Nucleic Acids Res. 46, W242\u2013w245 (2018).","journal-title":"Nucleic Acids Res."},{"key":"73241_CR51","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"73241_CR52","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73241_CR53","doi-asserted-by":"publisher","first-page":"e80467","DOI":"10.1371\/journal.pone.0080467","volume":"8","author":"J Lotem","year":"2013","unstructured":"Lotem, J. et al. Runx3-mediated transcriptional program in cytotoxic lymphocytes. PLoS ONE 8, e80467 (2013).","journal-title":"PLoS ONE"},{"key":"73241_CR54","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res. 47, D1211\u2013D1217 (2019).","journal-title":"Nucleic Acids Res."},{"key":"73241_CR55","doi-asserted-by":"publisher","first-page":"D1522","DOI":"10.1093\/nar\/gkab1081","volume":"50","author":"T Chen","year":"2022","unstructured":"Chen, T. et al. iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 50, D1522\u2013d1527 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73241-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:01:54Z","timestamp":1784289714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73241-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73241"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73241-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6448"}}